# Paclitaxel in Treating Patients With Refractory or Recurrent Acute Leukemia or Chronic Myelogenous Leukemia

> **NCT00003230** · PHASE1,PHASE2 · COMPLETED · sponsor: **Swiss Cancer Institute** · enrollment: 33 (estimated)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** paclitaxel

## Key facts

- **NCT ID:** NCT00003230
- **Lead sponsor:** Swiss Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-01
- **Primary completion:** 2000-07
- **Final completion:** 2000-07
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2012-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003230

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003230, "Paclitaxel in Treating Patients With Refractory or Recurrent Acute Leukemia or Chronic Myelogenous Leukemia". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00003230. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*